- Director, Seidman Cancer Center Lab, UH Cleveland Medical Center
- Director, Adult Hemophilia Program, UH Cleveland Medical Center
- Professor, CWRU School of Medicine
- Anticoagulant Management
- Atypical Hemolytic Uremic Syndrome (aHUS)
- Benign Hematology
- Hemostasis and Thrombosis
- Hereditary Angioedema
Patient Experience Reviews
4.9 out of 5
Patient Comments (8)
Reviewed On 9/1/2021
Reviewed On 8/1/2021
He is a great doctor and has helped me many times.
Reviewed On 4/1/2021
excellent. very personable. explained in layman terms. highly recommend
Reviewed On 4/1/2021
Appreciated how he listened to me and watched as I responded to his questions; very pleasant and approachable manner
Reviewed On 3/1/2021
Excellent experience. the caref provider really seemed interested inall my health issues
Reviewed On 2/1/2021
Love Dr. Schmaier and his staff. *** and *** are exceptional.
Reviewed On 12/1/2020
this was my best experience with UH. the doctor took time with me and understood my complete medical situation even though parts didn't apply to his specialty. he was kind & showed genuine concern for me
Reviewed On 11/1/2020
Always very thorough in physical examination and honest in all discussions. Answers all the hard questions with sincerity and professionalism. If there is an area of concern, always follows up with an email or phone call which is so appreciated.
- Medical Oncology - American Board of Internal Medicine
- Hematology - American Board of Internal Medicine
- Internal Medicine - American Board of Internal Medicine
Research Fellowship | Hematology/Oncology
Hematology/Oncology - Temple University Hospital (1979 - 1980)
Fellowship | Hematology/Oncology
Hematology/Oncology - Hospital Of The University Of Pennsylvania (1977 - 1979)
Residency | Internal Medicine
Internal Medicine - Temple University Hospital (1975 - 1977)
Internship | Internal Medicine
Internal Medicine - Temple University (1974 - 1975)
Virginia Commonwealth University School Of Medicine (1974)
University Of Virginia (1970)
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Alvin Schmaier disclosed the following Outside Relationships with Industry:
- - Lippincott Publishers - Intellectual Property